TGF-β1
関連文献

“Transforming growth factor beta in tissue fibrosis”. N. Engl. J. Med. 331 (19):  1286–92. (1994). doi:10.1056/NEJM199411103311907. PMID 7935686.
“Latent transforming growth factor-beta: structural features and mechanisms of activation”. Kidney Int. 51 (5):  1376–82. (1997). doi:10.1038/ki.1997.188. PMID 9150447.
“The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins”. J. Biol. Chem. 274 (27):  18843–6. (1999). doi:10.1074/jbc.274.27.18843. PMID 10383378.
“HIV-1 Tat: immunosuppression via TGF-beta1 induction”. Immunol. Today 20 (8):  384–5. (1999). doi:10.1016/S0167-5699(99)01497-8. PMID 10431160.
“Association of polymorphisms of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis”. Pharmacogenetics 11 (9):  765–71. (2001). doi:10.1097/00008571-200112000-00004. PMID 11740340.
“TGF-β: Receptors, Signaling Pathways and Autoimmunity”. TGF-beta: receptors, signaling pathways and autoimmunity. Current Directions in Autoimmunity. 5. (2002). 62–91. doi:10.1159/000060548. ISBN 978-3-8055-7308-5. PMID 11826761
“Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21”. Leuk. Lymphoma 43 (1):  51–7. (2002). doi:10.1080/10428190210195. PMID 11908736.
“TGF-beta signal transduction and mesangial cell fibrogenesis”. Am. J. Physiol. Renal Physiol. 284 (2):  F243–52. (2003). doi:10.1152/ajprenal.00300.2002. PMID 12529270.
“Epithelial-mesenchymal transition and its implications for fibrosis”. J. Clin. Invest. 112 (12):  1776–84. (2003). doi:10.1172/JCI20530. PMC 297008. PMID 14679171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC297008/.
“Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis”. Arterioscler. Thromb. Vasc. Biol. 24 (3):  399–404. (2004). doi:10.1161/01.ATV.0000114567.76772.33. PMID 14699019.
“TGFbeta and Wnt pathway cross-talk”. Cancer Metastasis Rev. 23 (1–2):  53–61. (2004). doi:10.1023/A:1025811012690. PMID 15000149.
“Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy”. Curr. Diab. Rep. 4 (6):  447–54. (2004). doi:10.1007/s11892-004-0055-z. PMID 15539010.
“Integrin-mediated activation of latent transforming growth factor beta”. Cancer Metastasis Rev. 24 (3):  395–402. (2005). doi:10.1007/s10555-005-5131-6. PMID 16258727.
“Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets”. J. Cell. Mol. Med. 10 (1):  76–99. (2006). doi:10.1111/j.1582-4934.2006.tb00292.x. PMC 3933103. PMID 16563223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933103/.
“Escaping from the TGFbeta anti-proliferative control”. Carcinogenesis 27 (11):  2148–56. (2006). doi:10.1093/carcin/bgl068. PMID 16698802.
“Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling”. Proc Am Thorac Soc 3 (5):  418–23. (2006). doi:10.1513/pats.200602-017AW. PMC 2658706. PMID 16799085. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658706/.
“Transforming growth factor-beta: innately bipolar”. Curr. Opin. Immunol. 19 (1):  55–62. (2007). doi:10.1016/j.coi.2006.11.008. PMID 17137775. https://zenodo.org/record/1258845.
“TGF-beta1: a novel target for cardiovascular pharmacology”. Cytokine Growth Factor Rev. 18 (3–4):  279–86. (2007). doi:10.1016/j.cytogfr.2007.04.005. PMID 17485238.
“Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update”. J Cereb Blood Flow Metab 40 (9):  1752–1768. (May 2020). doi:10.1177/0271678X20923551. PMC 7446569. PMID 32423330. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446569/.